433
Participants
Start Date
December 31, 2009
Primary Completion Date
July 31, 2013
Study Completion Date
October 31, 2013
Golimumab 50 mg SC
Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
Golimumab 2 mg/kg IV
Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
Methotrexate (MTX)
Participants will continue taking their current Methotrexate (MTX) treatment regimen.
Placebo SC
Placebo matched to golimumab SC injection every 4 weeks.
Placebo IV
Placebo matched to golimumab intravenous infusion every 8 weeks.
Birmingham
Huntsville
Tuscaloosa
Mesa
Phoenix
Hot Springs
Little Rock
Covina
Hemet
Loma Linda
Long Beach
Murrieta
Santa Maria
Santa Monica
Torrance
Van Nuys
Victorville
Whittier
Bridgeport
Hamden
Trumbull
Aventura
Fort Lauderdale
Jacksonville
Naples
Orange Park
Orlando
Palm Harbor
Plantation
Sarasota
Tampa
Duluth
Coeur d'Alene
Idaho Falls
Rockford
South Bend
Bettendorf
Kansas City
Bowling Green
Monroe
New Orleans
Wheaton
Rochester
Flowood
Tupelo
Clayton
Florissant
Lincoln
Freehold
Brooklyn
Mineola
Plainview
Rochester
Smithtown
Charlotte
Greenville
Hickory
Wilmington
Akron
Columbus
Mayfield
Middleburg Heights
Edmond
Oklahoma City
Lake Oswego
Bethlehem
Duncansville
West Reading
Wexford
Charleston
Columbia
Myrtle Beach
Hixson
Jackson
Kingsport
Knoxville
Nashville
Austin
Carrollton
Dallas
Houston
San Antonio
Arlington
Chesapeake
Seattle
Spokane
Beckley
Clarksburg
Glendale
Vienna
Brussels
Genk
Ghent
Liège
Merksem
Edmonton
Kelowna
Vancouver
Winnipeg
Hamilton
Montreal
Québec
St. Johns
Hamburg
Herne
München
Ratingen
Heraklion- Crete
Thessalonikis
Stockholm
Cannock
Leeds
London
Manchester
Merseyside
Newcastle upon Tyne
Wigan
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Janssen Biotech, Inc.
INDUSTRY